Here we show that expression of the EBV immediate-early protein BZLF1 is restricted to Blimp1-positive epithelial cells in OHL. Luciferase assays revealed Blimp1-dependent induction of the BZLF1 promoter Zp in epithelial cell lines. Expression of ZEB1, a negative regulator of Zp, and of Xbp-1, which mediates the Blimp1 effect on Zp in B-cells, was not affected by enforced Blimp1 expression. Moreover, Xbp-1 protein expression was not detected in differentiated epithelial cells of OHL. Thus, Blimp1 induces BZLF1 expression in epithelial cells independently of ZEB1 and Xbp-1. In contrast to epithelial cells of OHL, BZLF1 expression was also observed in Blimp1-negative lymphoid cells in infectious mononucleosis tonsils, suggesting that EBV replication in B-cells may be induced independently of terminal differentiation.
Epstein-Barr virus (EBV) is a B-lymphotropic human herpesvirus infecting .90 % of the adult population worldwide. Primary infection in childhood is usually asymptomatic but may cause a clinical syndrome, infectious mononucleosis (IM), when delayed into adolescence or early adulthood. Following primary infection, a lifelong persistent latent infection of memory B-cells is established. Infectious virus particles are released into the saliva, but their cellular source has been controversial (Niedobitek & Young, 1994) . It is now clear that EBV may replicate in B-cells as well as in oral squamous epithelial cells. In both cellular compartments, the switch from latent to lytic infection is triggered by expression of the immediate-early gene BZLF1, which is necessary and sufficient to activate the EBV lytic cascade (Rooney et al., 1989; Miller, 1990) . Various lines of evidence have indicated that EBV replication depends on cellular differentiation. Immunohistochemical analysis of B-cells in IM tonsils suggested a restriction of virus replication to cells with plasma-cell morphology (Crawford & Ando, 1986; Niedobitek et al., 1997) . Furthermore, terminal differentiation of B-cells towards plasma cells initiates the lytic cycle in vivo (Laichalk & Thorley-Lawson, 2005) . Similarly, it has been suggested that, in epithelial cells of oral hairy leukoplakia (OHL), an AIDS-associated lesion of the tongue mucosa, EBV replicates in a differentiation-dependent manner (Young et al., 1991) .
Plasma-cell differentiation is regulated by B-lymphocyteinduced maturation protein (Blimp)1 (Shapiro-Shelef et al., 2003) . By repressing Pax5, Blimp1 indirectly activates the Xbox-binding protein Xbp-1 (Lin et al., 2002) . Induction of BZLF1 expression by binding of Xbp-1 to the BZLF1 promoter Zp has been demonstrated in B-cells, but not in epithelial cells (Sun & Thorley-Lawson, 2007) . In contrast, Bhende et al. (2007) showed that Xbp-1 transactivates BZLF1 only in combination with activated protein kinase D in B-lymphocytes and epithelial cells. It has been postulated that entry into the lytic cycle of EBV infection is subject to regulation by cellular and viral factors that differ between B-cells and epithelial cells (Lagenaur & Palefsky, 1999; Shannon-Lowe et al., 2009) . As already demonstrated for B-cells, activity of Zp in epithelial cells increases strongly upon induction of terminal differentiation in a human squamous epithelial cell line (Karimi et al., 1995) . More recently, Blimp1 has also been identified as a necessary transcription factor for the terminal differentiation of epithelial cells (Magnú sdó ttir et al., 2007) . We therefore hypothesized that Blimp1 expression may play a role in the lytic replication of EBV in epithelial cells by inducing the activation of the BZLF1 promoter Zp. Details of experimental procedures are described in Supplementary Methods (available in JGV Online).
To test this hypothesis, five samples of EBV-associated OHL, the best-characterized model of EBV replication in epithelial cells in vivo (Greenspan et al., 1985) , were subjected to immunohistochemistry for the detection of Blimp1 using a Blimp1-specific rabbit antiserum . This revealed nuclear labelling of epithelial cells in the upper, differentiated cell layers [ Fig. 1a(i) ]. Some of the small nuclei in the superficial parakeratotic layer appear to be Blimp1-negative. It is unclear whether this is due to a genuine downregulation of protein expression or to poor protein accessibility in these condensed nuclei. Blimp1 protein was undetectable in the basal epithelial cells. Since in B-cells, Blimp-1 exerts its regulatory effect on Zp through Xbp-1 (Lin et al., 2002) , we also studied Xbp-1 expression in OHL using immunohistochemistry by using an Xbp-1-specific rabbit polyclonal antibody (ab37152; Abcam) and tyramide signal amplification. In contrast to Blimp1, Xbp-1 was not expressed in the differentiated epithelial cells of OHL [ Fig.  1a (ii)], whilst a few epithelial cells in the Blimp1-negative basal cell layers displayed distinct nuclear Xbp-1 expression [ Fig. 1a(ii) , inset]. Thus, Blimp1 and Xbp-1 are expressed in non-overlapping cell populations in OHL. The function of Xbp-1 in basal epithelial cells is currently unclear. As the antibody employed recognizes both spliced and unspliced isoforms of Xbp-1, it is unclear which isoform(s) are expressed in these cells. However, as these cells are EBVnegative in OHL (see below) and the superficial Blimp1-positive cells are negative for Xbp-1, it is not likely that Xbp-1 is required for EBV replication in squamous epithelial cells of OHL.
Subsequently, we characterized EBV infection in these samples. Immunohistochemistry using mAb BZ1 revealed nuclear expression of BZLF1 in foci of differentiated epithelial cells near the surface of the lesions [Fig. 1a(iii) ]. Using an EBNA1-specific mAb (clone 1H4), a similar pattern was observed (not shown). Notably, no specific staining was detected in basal epithelial cells of OHL using immunohistochemistry for the detection of BZLF1 or EBNA1, as reported previously (Niedobitek et al., 1991; Murray et al., 1996) . Furthermore, double-staining immunohistochemistry revealed that the late viral antigen, membrane antigen (MA, gp 350/220, BLLF1, mAb OT6; Herrmann et al., 2002) , is expressed exclusively in Blimp1-positive epithelial cells of OHL [ Fig. 1a(iv) ]. This is in keeping with the notion that these terminally differentiated epithelial cells are capable of supporting full virus replication (Rabanus et al., 1991; Herrmann et al., 2002; Frangou et al., 2005) .
Next, we analysed the co-localization of Blimp1 and BZLF1 in OHL by double-staining immunofluorescence (Fig. 1b) . The overlay of Blimp1-specific [ Fig. 1b(i) , green] and BZLF1-specific [ Fig. 1b(ii) , red] signals showed that Blimp1 expression was detectable in epithelial cell nuclei of the superficial differentiated epithelial cell layer, and that expression of BZLF1 was restricted to foci of epithelial cells within this Blimp1-positive cell layer [ Fig. 1b(iii) ]. Notably, whilst there were many Blimp1
2 cells, the reverse, i.e. BZLF1
+

/Blimp1
2 cells, was not observed in OHL. Thus, these observations are in keeping with a possible role for Blimp1 in the induction of EBV replication.
It has been reported that EBV replication in tonsils is virtually restricted to highly CD38-expressing plasma cells (Laichalk & Thorley-Lawson, 2005) . For comparison, we therefore analysed the co-localization of Blimp1 and BZLF1 in B-cells of tonsils from four patients with IM and undertook a detailed quantitative analysis (Fig. 1c) . Double-staining immunofluorescence revealed Blimp1 expression [green, Fig. 1c Fig. 1c(iii) ]. Thus, between 31 and 62 % of BZLF1-expressing cells lacked detectable expression of Blimp1. This is in contrast to our observations in epithelial cells in OHL and may reflect different regulatory mechanisms of BZLF1 expression in both cell types. The differences between our and previously published results are probably due to different technical approaches. Whilst Having shown that BZLF1 expression in epithelial cells of OHL is restricted to Blimp1-positive cells, we next analysed whether Blimp1 can induce the BZLF1 promoter Zp. Parental HEK293 (Fig. 2b) and HeLa (Fig. 2c ) cells did not express Blimp1 protein, as shown by Western blot analysis using mAb 3H2E8 (Chang et al., 2002) . Next, we cotransfected the Blimp1-negative epithelial cell line HeLa and HEK293T cells with the Blimp1-expressing plasmid pEXP4-Blimp1 containing the complete human Blimp1 cDNA, the Zp reporter construct pHEBo-Zp-Luc harbouring the firefly luciferase ORF under control of Zp, and the Renilla luciferase reporter plasmid pRL-TK (Binné et al., 2002) . Forty-eight hours post-transfection, dual luciferase assays were conducted. The Renilla luciferase activity served for transfection quantification. The relative firefly luciferase activity was calculated from the quotient of firefly and Renilla luciferase activities. Ectopic Blimp1 expression strongly induced BZLF1 promoter Zp activity in HEK293T and HeLa cells (Fig. 2a) . These data strongly imply a role for Blimp1 in the induction of the lytic transactivator BZLF1 in epithelial cells.
As Blimp1 functions as a transcriptional repressor, it is likely that the effect of Blimp1 on Zp activity is due to the repression of an inhibitory cellular factor rather than to a direct action of Blimp1 on Zp. One promising candidate is ZEB1, a cellular transcription factor of the zinc-finger Ebox-binding proteins, which inhibits lytic activation at the proximal Zp promoter structures ZV and ZV9 (Yu et al., 2007) . Bioinformatic analysis of the ZEB1 59-UTR using rVista 2.0 (http://rvista.dcode.org/) indicated two putative binding sites for the transcriptional repressor Blimp1. To analyse whether Blimp1 expression downregulates ZEB1, we ectopically overexpressed Blimp1 in HEK293 cells for 48 h and analysed ZEB1 expression by Western blotting and RT-PCR. However, the expression of Blimp1 showed no effect on the expression levels of ZEB1 protein [ Fig.  2b(i) ] or mRNA [ Fig. 2b(ii) ]. This suggests that the effect of Blimp1 on Zp activity is not mediated by downregulation of ZEB1. Thus, it will be important to examine possible effects of Blimp1 on other negative regulators of BZLF1 expression (Montalvo et al., 1995; Thomas et al., 2003; Ellis et al., 2010) .
In B-cells, it has been shown that Blimp1 represses Pax5, which in turn is a negative regulator of Xbp-1 (Lin et al., 2002) . Xbp-1 can transactivate the Zp promoter in B-cells (Sun & Thorley-Lawson, 2007) . Using RT-PCR followed by PstI digestion of the PCR product, both unspliced and activated spliced variant Xbp-1 transcripts were detected in Blimp1-negative HeLa and HEK293 cells [ Fig. 2d(i) ]. We next investigated whether Blimp1 overexpression in HEK293 cells had any effect on the expression of Xbp-1. Again, HEK293 cells were transiently transfected with Blimp1 for 72 h. This had no effect on the expression of Xbp-1 RNA transcripts [ Fig. 2d(ii) ]. Specifically, the ratio of spliced and unspliced Xbp-1 was not changed by Blimp1 transfection in HEK293 cells compared with mocktransfected cells. These results indicate that although Xbp-1 is expressed in HEK293 cells, it is not subject to Blimp1-mediated regulation, in contrast to B-cells. Furthermore, although activated Xbp-1 is present in HeLa and HEK293 cells, it does not seem to be able to activate Zp in this context, as in both cell lines Zp activity was minimal in the absence of exogenous Blimp1. This might be due to the lack of an activating co-factor of Xbp-1, as it has been shown that Xbp-1 activates the Zp promoter in the presence of protein kinase C, but not in its absence (Bhende et al., 2007) . Moreover, these results suggest that Blimp1 can induce the Zp promoter in HEK293 cells independently of Xbp-1. This notion is also supported by our observation that, in OHL tissues, Xbp-1 protein expression is not detectable in superficial epithelial cells, which co-express Blimp1 and viral lytic antigens. Moreover, we found no expression of Pax5 in epithelial cells of tonsils or OHL (data not shown). In combination, these observations support the hypothesis that the mechanism of Zp activation in epithelial cells is different from the pathway used in B-cells.
In summary, we show that BZLF1 expression in EBVpositive OHL is restricted to Blimp1-positive differentiated (ii) Subsequently, HEK293 cells were transiently transfected with pEXP4-Blimp1 or pEXP4-MCS for 72 h. RT-PCR analysis and PstI digestion showed that the ratio of spliced and unspliced Xbp-1 was not changed by exogenous Blimp1 expression (441 bp, unspliced, undigested; 415 bp, spliced, 294 bp, unspliced, PstIdigested; 147 bp, unspliced, . Data shown are representative of three independent experiments. epithelial cells. In vitro, ectopic Blimp1 expression activates the BZLF1 promoter in epithelial cells. This effect is not due to Blimp1-mediated differential expression of the cellular transcription factors ZEB1 or Xbp-1. In contrast to epithelial cells of OHL, BZLF1 expression does occur in Blimp1-negative in addition to Blimp1-positive lymphocytes in IM tonsils, suggesting that other factors may substitute for Blimp1 in lymphocytes in the induction of EBV lytic replication.
